Bueno Muiño Coralia, Martín Miguel, Del Monte-Millán María, García-Saénz José Ángel, López-Tarruella Sara
Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, 28009 Madrid, Spain.
Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigacion Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Geicam, Universidad Complutense, 28007 Madrid, Spain.
Cancers (Basel). 2022 Jan 20;14(3):512. doi: 10.3390/cancers14030512.
Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed.
乳腺癌患者的长期预后因分子亚型而异，其中HER2-E是最具侵袭性的一种。临床实践的进展极大地改变了HER2阳性乳腺癌的预后。采用风险适应性策略实现个体化治疗很有必要。基于临床病理因素的风险，人们鼓励采用降阶梯治疗方法。分子基因分型可以进一步准确界定对抗HER2治疗敏感的HER2依赖性肿瘤，从而避免不必要的治疗。本文讨论了HER2阳性乳腺癌从免疫化学向分子谱分析的转变。
